2016.01.18 03:57 cranialitysounds The House of the Underground Voice
2018.02.20 22:49 ani_shira Redditsvision Song Contest
2024.05.18 18:59 djavulensfitta Short story written by Joost (Brüders auf Berlin)
2024.05.18 16:17 Freeman_Alex [WTS] ⚜️⚜️⚜️Freeman Shipyard Store vol.4⚜️⚜️⚜️ OC LTI Ursa Medivac +Respite Paint $55 ⚜️OC LTI Pulse/LX +Dominion Paint $25 ⚜️Prowler to Hull D CCU $45 ⚜️Hull D to Orion CCU $50 ⚜️CHEAP WARBOND CCU ⚜️QuickSALE ⚜️Open24/7 ⚜️Good Prices&Trade History ⚜️Rare Paints ⚜️JUST WRITE ME
CCU - FROM | -> TO | Save $ | Warbond Bonus | Price |
---|---|---|---|---|
Razor | Retaliator Base | - | - | $7 |
Prowler | 600i BIS 2953 | 🔥 | +paint & poster | $40 |
Hull D | Orion | $50 | 120m | $50 |
Prowler | Hull D | $65 | - | $45 |
Razor | SRV | $15 | - | $5 |
Quantity | Price, $ |
---|---|
1 referral | $-- |
5+ referral | $-- for each |
Item | Insurance | Includes | Price |
---|---|---|---|
UEE EXPLORATION 2948 PACK | LTI | SC+SQ42+VFG+20k | $800 |
SCOUNDREL PACK | LTI | SC+SQ42+VFG+20k | $740 |
ENTREPRENEUR PACK | LTI | SC+SQ42+VFG+20k | $640 |
SHIP | TARGET SHIP | < | Upgrade from | Price |
---|---|---|---|---|
400I | ||||
400I | < | CONSTELLATION ANDROMEDA | $15 | |
600I EXPLORER | ||||
600I EXPLORER | < | PROWLER | $70 | |
ARROW | ||||
ARROW | < | AURORA MR | $50 | |
ARROW | < | MUSTANG ALPHA | $50 | |
ARROW | < | C8X PISCES EXPEDITION | $35 | |
ARROW | < | 100i | $30 | |
ARROW | < | AVENGER TITAN | $25 | |
ARROW | < | RELIANT KORE | $15 | |
CATERPILLAR BEST IN SHOW EDITION | ||||
CATERPILLAR BISE | < | VANGUARD HARBINGER | $100 | |
CORSAIR | ||||
CORSAIR | < | TAURUS | $60 | |
CRUCIBLE | ||||
CRUCIBLE | < | STARFARER GEMINI | $21 | |
CUTLASS BLACK BEST IN SHOW EDITION | ||||
CUTLASS BLACK BISE | < | GLADIUS | $70 | |
CUTLASS RED Subscriber | ||||
CUTLASS RED Subscriber | < | F7C-S HORNET GHOST | $25 | |
CUTLASS BLUE | ||||
CUTLASS BLUE | < | PROSPECTOR | $30 | |
DEFENDER | ||||
DEFENDER | < | CORSAIR | $15 | |
DEFENDER | < | HORNET F7C-M HEARTSEEKER | $37 | |
GLADIUS | ||||
GLADIUS | < | AURORA MR | $65 | |
GLADIUS | < | MUSTANG ALPHA | $65 | |
GLADIUS | < | C8X PISCES EXPEDITION | $50 | |
GLADIUS | < | 100i | $45 | |
GLADIUS | < | AVENGER TITAN | $40 | |
GLADIUS | < | RELIANT KORE | $30 | |
GLADIUS | < | ARROW | $20 | |
HAMMERHEAD | ||||
HAMMERHEAD | < | CARRACK | $150 | |
HAMMERHEAD | < | CARRACK EXPEDITION W/C8X | $100 | |
HULL C | ||||
HULL C | < | CATERPILLAR | $175 | |
MERCHANTMAN | ||||
MERCHANTMAN | < | STARFARER GEMINI | $300 | |
MERCHANTMAN | < | ARGO MOLE | $345 | |
NAUTILUS | ||||
NAUTILUS | < | CARRACK | $175 | |
PERSEUS | ||||
PERSEUS | < | CARRACK Expedition W/C8X | $40 | |
PERSEUS | < | CARRACK | $90 | |
PERSEUS | < | ORION | $115 | |
PERSEUS | < | 600I EXPLORER | $220 | |
PERSEUS | < | MERCHANTMAN | $248 | |
PERSEUS | < | ARGO MOLE | $380 | |
PERSEUS | < | ANDROMEDA | $485 | |
POLARIS | ||||
POLARIS | < | PERSEUS | $70 | |
POLARIS | < | HAMMERHEAD | $70 | |
POLARIS | < | NAUTILUS | $60 | |
POLARIS | < | CARRACK | $250 | |
RECLAIMER BIS 2949 | ||||
RECLAIMER BIS 2949 | < | VALKYRIE | $300 | |
SAN'TOK.YĀI | ||||
SAN'TOK.YĀI | < | HORNET F7C-M HEARTSEEKER | $37 |
2024.05.17 18:50 Freeman_Alex [WTS] ⚜️⚜️⚜️Freeman Shipyard Store vol.4⚜️⚜️⚜️ OC LTI Ursa Medivac +Respite Paint $55 ⚜️OC LTI Pulse/LX +Dominion Paint $25 ⚜️Prowler to Hull D CCU $45 ⚜️Hull D to Orion CCU $50 ⚜️CHEAP WARBOND CCU ⚜️QuickSALE ⚜️Open24/7 ⚜️Good Prices&Trade History ⚜️Rare Paints ⚜️JUST WRITE ME
CCU - FROM | -> TO | Save $ | Warbond Bonus | Price |
---|---|---|---|---|
Razor | Retaliator Base | - | - | $7 |
Prowler | 600i BIS 2953 | 🔥 | +paint & poster | $40 |
Hull D | Orion | $50 | 120m | $50 |
Prowler | Hull D | $65 | - | $45 |
Razor | SRV | $15 | - | $5 |
Quantity | Price, $ |
---|---|
1 referral | $-- |
5+ referral | $-- for each |
Item | Insurance | Includes | Price |
---|---|---|---|
UEE EXPLORATION 2948 PACK | LTI | SC+SQ42+VFG+20k | $800 |
SCOUNDREL PACK | LTI | SC+SQ42+VFG+20k | $740 |
ENTREPRENEUR PACK | LTI | SC+SQ42+VFG+20k | $640 |
SHIP | TARGET SHIP | < | Upgrade from | Price |
---|---|---|---|---|
400I | ||||
400I | < | CONSTELLATION ANDROMEDA | $15 | |
600I EXPLORER | ||||
600I EXPLORER | < | PROWLER | $70 | |
ARROW | ||||
ARROW | < | AURORA MR | $50 | |
ARROW | < | MUSTANG ALPHA | $50 | |
ARROW | < | C8X PISCES EXPEDITION | $35 | |
ARROW | < | 100i | $30 | |
ARROW | < | AVENGER TITAN | $25 | |
ARROW | < | RELIANT KORE | $15 | |
CATERPILLAR BEST IN SHOW EDITION | ||||
CATERPILLAR BISE | < | VANGUARD HARBINGER | $100 | |
CORSAIR | ||||
CORSAIR | < | TAURUS | $60 | |
CRUCIBLE | ||||
CRUCIBLE | < | STARFARER GEMINI | $21 | |
CUTLASS BLACK BEST IN SHOW EDITION | ||||
CUTLASS BLACK BISE | < | GLADIUS | $70 | |
CUTLASS RED Subscriber | ||||
CUTLASS RED Subscriber | < | F7C-S HORNET GHOST | $25 | |
CUTLASS BLUE | ||||
CUTLASS BLUE | < | PROSPECTOR | $30 | |
DEFENDER | ||||
DEFENDER | < | CORSAIR | $15 | |
DEFENDER | < | HORNET F7C-M HEARTSEEKER | $37 | |
GLADIUS | ||||
GLADIUS | < | AURORA MR | $65 | |
GLADIUS | < | MUSTANG ALPHA | $65 | |
GLADIUS | < | C8X PISCES EXPEDITION | $50 | |
GLADIUS | < | 100i | $45 | |
GLADIUS | < | AVENGER TITAN | $40 | |
GLADIUS | < | RELIANT KORE | $30 | |
GLADIUS | < | ARROW | $20 | |
HAMMERHEAD | ||||
HAMMERHEAD | < | CARRACK | $150 | |
HAMMERHEAD | < | CARRACK EXPEDITION W/C8X | $100 | |
HULL C | ||||
HULL C | < | CATERPILLAR | $175 | |
MERCHANTMAN | ||||
MERCHANTMAN | < | STARFARER GEMINI | $300 | |
MERCHANTMAN | < | ARGO MOLE | $345 | |
NAUTILUS | ||||
NAUTILUS | < | CARRACK | $175 | |
PERSEUS | ||||
PERSEUS | < | CARRACK Expedition W/C8X | $40 | |
PERSEUS | < | CARRACK | $90 | |
PERSEUS | < | ORION | $115 | |
PERSEUS | < | 600I EXPLORER | $220 | |
PERSEUS | < | MERCHANTMAN | $248 | |
PERSEUS | < | ARGO MOLE | $380 | |
PERSEUS | < | ANDROMEDA | $485 | |
POLARIS | ||||
POLARIS | < | PERSEUS | $70 | |
POLARIS | < | HAMMERHEAD | $70 | |
POLARIS | < | NAUTILUS | $60 | |
POLARIS | < | CARRACK | $250 | |
RECLAIMER BIS 2949 | ||||
RECLAIMER BIS 2949 | < | VALKYRIE | $300 | |
SAN'TOK.YĀI | ||||
SAN'TOK.YĀI | < | HORNET F7C-M HEARTSEEKER | $37 |
2024.05.17 17:09 MightBeneficial3302 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to Stocks_Picks [link] [comments] https://preview.redd.it/icuhusjq501d1.png?width=300&format=png&auto=webp&s=3e438805afc9829b38efdd03af28fbeafebd63fd NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.17 17:09 MightBeneficial3302 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to SmallCapStocks [link] [comments] https://preview.redd.it/a4l0pbtp501d1.png?width=300&format=png&auto=webp&s=0355d3df17ef6633b9f18f999d2eaadb376c995e NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.17 14:06 nt96 Play turns 25. How Moby became an odd overnight sensation
2024.05.17 00:54 ReggaetonPartyMane1 Best Reggaeton-Latin Rap Albums of the 2010's (Top 10) [The Finale]
2024.05.17 00:10 walmartreallysucks Derek Jeter is struggling?
https://preview.redd.it/ql3iav4s3v0d1.png?width=1398&format=png&auto=webp&s=4937e12260dfadb740c92c3cbf50befaa62a002a submitted by walmartreallysucks to baseballcirclejerk [link] [comments] Apparently ole Derek is not doing well in retirement; He has turned to doing subpar construction estimating. What did he mean by this? |
2024.05.16 20:13 Freeman_Alex [WTS] ⚜️⚜️⚜️Freeman Shipyard Store vol.4⚜️⚜️⚜️ OC LTI Pulse/LX +Dominion Paint $25 ⚜️Prowler to Hull D CCU $45 ⚜️Hull D to Orion CCU $50 ⚜️CHEAP WARBOND CCU ⚜️QuickSALE ⚜️Open24/7 ⚜️Good Prices&Trade History ⚜️Original LTI Concepts ⚜️Subscribers Exclusive Items ⚜️Rare Paints ⚜️JUST WRITE ME
CCU - FROM | -> TO | Save $ | Warbond Bonus | Price |
---|---|---|---|---|
Razor | Retaliator Base | - | - | $7 |
Prowler | 600i BIS 2953 | 🔥 | +paint & poster | $40 |
Hull D | Orion | $50 | 120m | $50 |
Prowler | Hull D | $65 | - | $45 |
Razor | SRV | $15 | - | $5 |
Quantity | Price, $ |
---|---|
1 referral | $-- |
5+ referral | $-- for each |
Item | Insurance | Includes | Price |
---|---|---|---|
UEE EXPLORATION 2948 PACK | LTI | SC+SQ42+VFG+20k | $800 |
SCOUNDREL PACK | LTI | SC+SQ42+VFG+20k | $740 |
ENTREPRENEUR PACK | LTI | SC+SQ42+VFG+20k | $640 |
SHIP | TARGET SHIP | < | Upgrade from | Price |
---|---|---|---|---|
400I | ||||
400I | < | CONSTELLATION ANDROMEDA | $15 | |
600I EXPLORER | ||||
600I EXPLORER | < | PROWLER | $70 | |
ARROW | ||||
ARROW | < | AURORA MR | $50 | |
ARROW | < | MUSTANG ALPHA | $50 | |
ARROW | < | C8X PISCES EXPEDITION | $35 | |
ARROW | < | 100i | $30 | |
ARROW | < | AVENGER TITAN | $25 | |
ARROW | < | RELIANT KORE | $15 | |
CATERPILLAR BEST IN SHOW EDITION | ||||
CATERPILLAR BISE | < | VANGUARD HARBINGER | $100 | |
CORSAIR | ||||
CORSAIR | < | TAURUS | $60 | |
CRUCIBLE | ||||
CRUCIBLE | < | STARFARER GEMINI | $21 | |
CUTLASS BLACK BEST IN SHOW EDITION | ||||
CUTLASS BLACK BISE | < | GLADIUS | $70 | |
CUTLASS RED Subscriber | ||||
CUTLASS RED Subscriber | < | F7C-S HORNET GHOST | $25 | |
CUTLASS BLUE | ||||
CUTLASS BLUE | < | PROSPECTOR | $30 | |
DEFENDER | ||||
DEFENDER | < | CORSAIR | $15 | |
DEFENDER | < | HORNET F7C-M HEARTSEEKER | $37 | |
GLADIUS | ||||
GLADIUS | < | AURORA MR | $65 | |
GLADIUS | < | MUSTANG ALPHA | $65 | |
GLADIUS | < | C8X PISCES EXPEDITION | $50 | |
GLADIUS | < | 100i | $45 | |
GLADIUS | < | AVENGER TITAN | $40 | |
GLADIUS | < | RELIANT KORE | $30 | |
GLADIUS | < | ARROW | $20 | |
HAMMERHEAD | ||||
HAMMERHEAD | < | CARRACK | $150 | |
HAMMERHEAD | < | CARRACK EXPEDITION W/C8X | $100 | |
HULL C | ||||
HULL C | < | CATERPILLAR | $175 | |
MERCHANTMAN | ||||
MERCHANTMAN | < | STARFARER GEMINI | $300 | |
MERCHANTMAN | < | ARGO MOLE | $345 | |
NAUTILUS | ||||
NAUTILUS | < | CARRACK | $175 | |
PERSEUS | ||||
PERSEUS | < | CARRACK Expedition W/C8X | $40 | |
PERSEUS | < | CARRACK | $90 | |
PERSEUS | < | ORION | $115 | |
PERSEUS | < | 600I EXPLORER | $220 | |
PERSEUS | < | MERCHANTMAN | $248 | |
PERSEUS | < | ARGO MOLE | $380 | |
PERSEUS | < | ANDROMEDA | $485 | |
POLARIS | ||||
POLARIS | < | PERSEUS | $70 | |
POLARIS | < | HAMMERHEAD | $70 | |
POLARIS | < | NAUTILUS | $60 | |
POLARIS | < | CARRACK | $250 | |
RECLAIMER BIS 2949 | ||||
RECLAIMER BIS 2949 | < | VALKYRIE | $300 | |
SAN'TOK.YĀI | ||||
SAN'TOK.YĀI | < | HORNET F7C-M HEARTSEEKER | $37 |
2024.05.16 16:05 MightBeneficial3302 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to PennyStocksCanada [link] [comments] https://preview.redd.it/bner3hufps0d1.png?width=300&format=png&auto=webp&s=b4c638d6dd2bc8ea5fee928b39043cd2c9e24433 NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.16 16:04 MightBeneficial3302 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to PennyCatalysts [link] [comments] https://preview.redd.it/42gkts9eps0d1.png?width=300&format=png&auto=webp&s=be3982af0e10b5262b3a5cea1231d3732566ccfb NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.15 21:01 Freeman_Alex [WTS] ⚜️⚜️⚜️Freeman Shipyard Store vol.4⚜️⚜️⚜️ OC LTI Pulse/LX +Dominion Paint $25 ⚜️Prowler to Hull D CCU $45 ⚜️Hull D to Orion CCU $50 ⚜️CHEAP WARBOND CCU ⚜️QuickSALE ⚜️Open24/7 ⚜️Good Prices&Trade History ⚜️Original LTI Concepts ⚜️Subscribers Exclusive Items ⚜️Rare Paints ⚜️JUST WRITE ME
CCU - FROM | -> TO | Save $ | Warbond Bonus | Price |
---|---|---|---|---|
Razor | Retaliator Base | - | - | $7 |
Prowler | 600i BIS 2953 | 🔥 | +paint & poster | $40 |
Hull D | Orion | $50 | 120m | $50 |
Prowler | Hull D | $65 | - | $45 |
Razor | SRV | $15 | - | $5 |
Quantity | Price, $ |
---|---|
1 referral | $-- |
5+ referral | $-- for each |
Item | Insurance | Price,$(CCU-ed) |
---|---|---|
Pulse +Dominion Paint | LTI | $25🔥 |
Pulse LX +Dominion Paint | LTI | $25🔥 |
F7C Hornet Mk II +Ironscale Paint | LTI | $160🔥 |
600I BIS 2953 +Paint&Poster OC | 10y | $575🔥 |
Redeemer BIS 2953 +Paint&Poster OC | 10y | $430🔥 |
Corsair BIS 2953 +Paint&Poster OC | 10y | $350🔥 |
Vulture BIS 2953 +Paint&Poster OC | 10y | $275🔥 |
600i Explorer BIS 2951 + Paint & Jacket CCU'd | LTI | $400🔥 |
MERCURY STAR RUNNER BIS 2951 + Paint & Jacket CCU'd | LTI | $210🔥 |
MERCURY STAR RUNNER BIS 2952 + RED ALERT Paint CCU'd | LTI | $260🔥 |
CARRACK BIS 2952 + RED ALERT Paint CCU'd | LTI | $600 |
LTI Upgrade - Reliant Kore to CNOU Nomad | LTI | $80 |
LTI Upgrade - 315P to CNOU Nomad | LTI | $100 |
M50 Subscriber Edition | LTI | $98 |
Cutlass RED Subscriber Edition | LTI | $133 |
Mantis Subscriber Edition | LTI | $148 |
Sabre Subscriber Edition | LTI | $168 |
Add-Ons - Endeavor Telescope Pod | 10y | $135 |
Add-Ons - Endeavor Biodome Pod | 10y | $110 |
Add-Ons - Endeavor Fuel Pod | 10y | $40 |
Add-Ons - AEGIS Idris P After Market Kit | LTI | $260 |
Item | Insurance | Includes | Price |
---|---|---|---|
UEE EXPLORATION 2948 PACK | LTI | SC+SQ42+VFG+20k | $800 |
SCOUNDREL PACK | LTI | SC+SQ42+VFG+20k | $740 |
ENTREPRENEUR PACK | LTI | SC+SQ42+VFG+20k | $640 |
SHIP | TARGET SHIP | < | Upgrade from | Price |
---|---|---|---|---|
400I | ||||
400I | < | CONSTELLATION ANDROMEDA | $15 | |
600I EXPLORER | ||||
600I EXPLORER | < | PROWLER | $70 | |
ARGO MOLE | ||||
ARGO MOLE | < | CONSTELLATION AQUILA | $7 | |
ARGO MOLE | < | MERCURY STAR RUNNER | $59 | |
ARGO MOLE | < | VANGUARD WARDEN | $59 | |
ARGO MOLE | < | RETALIATOR BOMBER | $43 | |
ARGO MOLE | < | VANGUARD SENTINEL | $43 | |
ARGO MOLE | < | APOLLO MEDIVAC | $43 | |
ARGO MOLE | < | ESPERIA VANDUUL BLADE | $43 | |
ARGO MOLE | < | VANGUARD HARBINGER | $27 | |
ARGO MOLE | < | REDEEMER | $70 | |
ARGO MOLE | < | HULL C | $70 | |
ARGO MOLE | < | APOLLO TRIAGE | $70 | |
ARROW | ||||
ARROW | < | AURORA MR | $50 | |
ARROW | < | MUSTANG ALPHA | $50 | |
ARROW | < | C8X PISCES EXPEDITION | $35 | |
ARROW | < | 100i | $30 | |
ARROW | < | AVENGER TITAN | $25 | |
ARROW | < | RELIANT KORE | $15 | |
CATERPILLAR BEST IN SHOW EDITION | ||||
CATERPILLAR BISE | < | VANGUARD HARBINGER | $100 | |
CORSAIR | ||||
CORSAIR | < | TAURUS | $60 | |
CRUCIBLE | ||||
CRUCIBLE | < | STARFARER GEMINI | $21 | |
CUTLASS BLACK BEST IN SHOW EDITION | ||||
CUTLASS BLACK BISE | < | GLADIUS | $70 | |
CUTLASS RED Subscriber | ||||
CUTLASS RED Subscriber | < | F7C-S HORNET GHOST | $25 | |
CUTLASS BLUE | ||||
CUTLASS BLUE | < | PROSPECTOR | $30 | |
DEFENDER | ||||
DEFENDER | < | CORSAIR | $15 | |
DEFENDER | < | HORNET F7C-M HEARTSEEKER | $37 | |
GLADIUS | ||||
GLADIUS | < | AURORA MR | $65 | |
GLADIUS | < | MUSTANG ALPHA | $65 | |
GLADIUS | < | C8X PISCES EXPEDITION | $50 | |
GLADIUS | < | 100i | $45 | |
GLADIUS | < | AVENGER TITAN | $40 | |
GLADIUS | < | RELIANT KORE | $30 | |
GLADIUS | < | ARROW | $20 | |
HAMMERHEAD | ||||
HAMMERHEAD | < | CARRACK | $150 | |
HAMMERHEAD | < | CARRACK EXPEDITION W/C8X | $100 | |
HULL C | ||||
HULL C | < | CATERPILLAR | $175 | |
MERCHANTMAN | ||||
MERCHANTMAN | < | STARFARER GEMINI | $300 | |
MERCHANTMAN | < | ARGO MOLE | $345 | |
NAUTILUS | ||||
NAUTILUS | < | CARRACK | $175 | |
PERSEUS | ||||
PERSEUS | < | CARRACK Expedition W/C8X | $40 | |
PERSEUS | < | CARRACK | $90 | |
PERSEUS | < | ORION | $115 | |
PERSEUS | < | 600I EXPLORER | $220 | |
PERSEUS | < | MERCHANTMAN | $248 | |
PERSEUS | < | ARGO MOLE | $380 | |
PERSEUS | < | ANDROMEDA | $485 | |
POLARIS | ||||
POLARIS | < | PERSEUS | $70 | |
POLARIS | < | HAMMERHEAD | $70 | |
POLARIS | < | NAUTILUS | $60 | |
POLARIS | < | CARRACK | $250 | |
RECLAIMER BIS 2949 | ||||
RECLAIMER BIS 2949 | < | VALKYRIE | $300 | |
SAN'TOK.YĀI | ||||
SAN'TOK.YĀI | < | HORNET F7C-M HEARTSEEKER | $37 |
2024.05.15 17:05 MightBeneficial3302 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to biotech_stocks [link] [comments] https://preview.redd.it/t44qslx9vl0d1.png?width=300&format=png&auto=webp&s=da369a64d53b8b85555ca79e169012d406cec164 NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.15 17:05 MightBeneficial3302 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to Biotechplays [link] [comments] https://preview.redd.it/uklt80l7vl0d1.png?width=300&format=png&auto=webp&s=8d602743504a5576451c90ca2a99b703f6a5b27b NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.15 00:01 Freeman_Alex [WTS] ⚜️⚜️⚜️Freeman Shipyard Store vol.4⚜️⚜️⚜️ OC LTI Pulse/LX +Dominion Paint $25 ⚜️Prowler to Hull D CCU $45 ⚜️Hull D to Orion CCU $50 ⚜️CHEAP WARBOND CCU ⚜️QuickSALE ⚜️Open24/7 ⚜️Good Prices&Trade History ⚜️Original LTI Concepts ⚜️Subscribers Exclusive Items ⚜️Rare Paints ⚜️JUST WRITE ME
CCU - FROM | -> TO | Save $ | Warbond Bonus | Price |
---|---|---|---|---|
Razor | Retaliator Base | - | - | $7 |
Prowler | 600i BIS 2953 | 🔥 | +paint & poster | $40 |
Hull D | Orion | $50 | 120m | $50 |
Prowler | Hull D | $65 | - | $45 |
Razor | SRV | $15 | - | $5 |
Quantity | Price, $ |
---|---|
1 referral | $-- |
5+ referral | $-- for each |
Item | Insurance | Price,$(CCU-ed) |
---|---|---|
Pulse +Dominion Paint | LTI | $25🔥 |
Pulse LX +Dominion Paint | LTI | $25🔥 |
F7C Hornet Mk II +Ironscale Paint | LTI | $160🔥 |
600I BIS 2953 +Paint&Poster OC | 10y | $575🔥 |
Redeemer BIS 2953 +Paint&Poster OC | 10y | $430🔥 |
Corsair BIS 2953 +Paint&Poster OC | 10y | $350🔥 |
Vulture BIS 2953 +Paint&Poster OC | 10y | $275🔥 |
600i Explorer BIS 2951 + Paint & Jacket CCU'd | LTI | $400🔥 |
MERCURY STAR RUNNER BIS 2951 + Paint & Jacket CCU'd | LTI | $210🔥 |
MERCURY STAR RUNNER BIS 2952 + RED ALERT Paint CCU'd | LTI | $260🔥 |
CARRACK BIS 2952 + RED ALERT Paint CCU'd | LTI | $600 |
LTI Upgrade - Reliant Kore to CNOU Nomad | LTI | $80 |
LTI Upgrade - 315P to CNOU Nomad | LTI | $100 |
M50 Subscriber Edition | LTI | $98 |
Cutlass RED Subscriber Edition | LTI | $133 |
Mantis Subscriber Edition | LTI | $148 |
Sabre Subscriber Edition | LTI | $168 |
Add-Ons - Endeavor Telescope Pod | 10y | $135 |
Add-Ons - Endeavor Biodome Pod | 10y | $110 |
Add-Ons - Endeavor Fuel Pod | 10y | $40 |
Add-Ons - AEGIS Idris P After Market Kit | LTI | $260 |
Item | Insurance | Includes | Price |
---|---|---|---|
UEE EXPLORATION 2948 PACK | LTI | SC+SQ42+VFG+20k | $800 |
SCOUNDREL PACK | LTI | SC+SQ42+VFG+20k | $740 |
ENTREPRENEUR PACK | LTI | SC+SQ42+VFG+20k | $640 |
SHIP | TARGET SHIP | < | Upgrade from | Price |
---|---|---|---|---|
400I | ||||
400I | < | CONSTELLATION ANDROMEDA | $15 | |
600I EXPLORER | ||||
600I EXPLORER | < | PROWLER | $70 | |
ARGO MOLE | ||||
ARGO MOLE | < | CONSTELLATION AQUILA | $7 | |
ARGO MOLE | < | MERCURY STAR RUNNER | $59 | |
ARGO MOLE | < | VANGUARD WARDEN | $59 | |
ARGO MOLE | < | RETALIATOR BOMBER | $43 | |
ARGO MOLE | < | VANGUARD SENTINEL | $43 | |
ARGO MOLE | < | APOLLO MEDIVAC | $43 | |
ARGO MOLE | < | ESPERIA VANDUUL BLADE | $43 | |
ARGO MOLE | < | VANGUARD HARBINGER | $27 | |
ARGO MOLE | < | REDEEMER | $70 | |
ARGO MOLE | < | HULL C | $70 | |
ARGO MOLE | < | APOLLO TRIAGE | $70 | |
ARROW | ||||
ARROW | < | AURORA MR | $50 | |
ARROW | < | MUSTANG ALPHA | $50 | |
ARROW | < | C8X PISCES EXPEDITION | $35 | |
ARROW | < | 100i | $30 | |
ARROW | < | AVENGER TITAN | $25 | |
ARROW | < | RELIANT KORE | $15 | |
CATERPILLAR BEST IN SHOW EDITION | ||||
CATERPILLAR BISE | < | VANGUARD HARBINGER | $100 | |
CORSAIR | ||||
CORSAIR | < | TAURUS | $60 | |
CRUCIBLE | ||||
CRUCIBLE | < | STARFARER GEMINI | $21 | |
CUTLASS BLACK BEST IN SHOW EDITION | ||||
CUTLASS BLACK BISE | < | GLADIUS | $70 | |
CUTLASS RED Subscriber | ||||
CUTLASS RED Subscriber | < | F7C-S HORNET GHOST | $25 | |
CUTLASS BLUE | ||||
CUTLASS BLUE | < | PROSPECTOR | $30 | |
DEFENDER | ||||
DEFENDER | < | CORSAIR | $15 | |
DEFENDER | < | HORNET F7C-M HEARTSEEKER | $37 | |
GLADIUS | ||||
GLADIUS | < | AURORA MR | $65 | |
GLADIUS | < | MUSTANG ALPHA | $65 | |
GLADIUS | < | C8X PISCES EXPEDITION | $50 | |
GLADIUS | < | 100i | $45 | |
GLADIUS | < | AVENGER TITAN | $40 | |
GLADIUS | < | RELIANT KORE | $30 | |
GLADIUS | < | ARROW | $20 | |
HAMMERHEAD | ||||
HAMMERHEAD | < | CARRACK | $150 | |
HAMMERHEAD | < | CARRACK EXPEDITION W/C8X | $100 | |
HULL C | ||||
HULL C | < | CATERPILLAR | $175 | |
MERCHANTMAN | ||||
MERCHANTMAN | < | STARFARER GEMINI | $300 | |
MERCHANTMAN | < | ARGO MOLE | $345 | |
NAUTILUS | ||||
NAUTILUS | < | CARRACK | $175 | |
PERSEUS | ||||
PERSEUS | < | CARRACK Expedition W/C8X | $40 | |
PERSEUS | < | CARRACK | $90 | |
PERSEUS | < | ORION | $115 | |
PERSEUS | < | 600I EXPLORER | $220 | |
PERSEUS | < | MERCHANTMAN | $248 | |
PERSEUS | < | ARGO MOLE | $380 | |
PERSEUS | < | ANDROMEDA | $485 | |
POLARIS | ||||
POLARIS | < | PERSEUS | $70 | |
POLARIS | < | HAMMERHEAD | $70 | |
POLARIS | < | NAUTILUS | $60 | |
POLARIS | < | CARRACK | $250 | |
RECLAIMER BIS 2949 | ||||
RECLAIMER BIS 2949 | < | VALKYRIE | $300 | |
SAN'TOK.YĀI | ||||
SAN'TOK.YĀI | < | HORNET F7C-M HEARTSEEKER | $37 |
2024.05.14 15:41 MightBeneficial3302 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to Wealthsimple_Penny [link] [comments] https://preview.redd.it/3j2x6d6bbe0d1.png?width=300&format=png&auto=webp&s=ab9b8537a609e57f81e15ea7bea8c4817172aa9b NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.14 15:40 MightBeneficial3302 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to CanadianStockExchange [link] [comments] https://preview.redd.it/kw4lbgl8be0d1.png?width=300&format=png&auto=webp&s=682c2587fdbda8b4608804c0d3b1e877a4624b4f NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.14 02:14 Aenima_314 Drum and Bass from NYC
2024.05.13 21:58 Freeman_Alex [WTS] ⚜️⚜️⚜️Freeman Shipyard Store vol.4⚜️⚜️⚜️ OC LTI Pulse/LX +Dominion Paint $25 ⚜️Prowler to Hull D CCU $45 ⚜️Hull D to Orion CCU $50 ⚜️CHEAP WARBOND CCU ⚜️QuickSALE ⚜️Open24/7 ⚜️Good Prices&Trade History ⚜️Original LTI Concepts ⚜️Subscribers Exclusive Items ⚜️Rare Paints ⚜️JUST WRITE ME
CCU - FROM | -> TO | Save $ | Warbond Bonus | Price |
---|---|---|---|---|
Razor | Retaliator Base | - | - | $7 |
Prowler | 600i BIS 2953 | 🔥 | +paint & poster | $40 |
Hull D | Orion | $50 | 120m | $50 |
Prowler | Hull D | $65 | - | $45 |
Razor | SRV | $15 | - | $5 |
Quantity | Price, $ |
---|---|
1 referral | $-- |
5+ referral | $-- for each |
Item | Insurance | Price,$(CCU-ed) |
---|---|---|
Pulse +Dominion Paint | LTI | $25🔥 |
Pulse LX +Dominion Paint | LTI | $25🔥 |
F7C Hornet Mk II +Ironscale Paint | LTI | $160🔥 |
600I BIS 2953 +Paint&Poster OC | 10y | $575🔥 |
Redeemer BIS 2953 +Paint&Poster OC | 10y | $430🔥 |
Corsair BIS 2953 +Paint&Poster OC | 10y | $350🔥 |
Vulture BIS 2953 +Paint&Poster OC | 10y | $275🔥 |
600i Explorer BIS 2951 + Paint & Jacket CCU'd | LTI | $400🔥 |
MERCURY STAR RUNNER BIS 2951 + Paint & Jacket CCU'd | LTI | $210🔥 |
MERCURY STAR RUNNER BIS 2952 + RED ALERT Paint CCU'd | LTI | $260🔥 |
CARRACK BIS 2952 + RED ALERT Paint CCU'd | LTI | $600 |
LTI Upgrade - Reliant Kore to CNOU Nomad | LTI | $80 |
LTI Upgrade - 315P to CNOU Nomad | LTI | $100 |
M50 Subscriber Edition | LTI | $98 |
Cutlass RED Subscriber Edition | LTI | $133 |
Mantis Subscriber Edition | LTI | $148 |
Sabre Subscriber Edition | LTI | $168 |
Add-Ons - Endeavor Telescope Pod | 10y | $135 |
Add-Ons - Endeavor Biodome Pod | 10y | $110 |
Add-Ons - Endeavor Fuel Pod | 10y | $40 |
Add-Ons - AEGIS Idris P After Market Kit | LTI | $260 |
Item | Insurance | Includes | Price |
---|---|---|---|
UEE EXPLORATION 2948 PACK | LTI | SC+SQ42+VFG+20k | $800 |
SCOUNDREL PACK | LTI | SC+SQ42+VFG+20k | $740 |
ENTREPRENEUR PACK | LTI | SC+SQ42+VFG+20k | $640 |
SHIP | TARGET SHIP | < | Upgrade from | Price |
---|---|---|---|---|
400I | ||||
400I | < | CONSTELLATION ANDROMEDA | $15 | |
600I EXPLORER | ||||
600I EXPLORER | < | PROWLER | $70 | |
ARGO MOLE | ||||
ARGO MOLE | < | CONSTELLATION AQUILA | $7 | |
ARGO MOLE | < | MERCURY STAR RUNNER | $59 | |
ARGO MOLE | < | VANGUARD WARDEN | $59 | |
ARGO MOLE | < | RETALIATOR BOMBER | $43 | |
ARGO MOLE | < | VANGUARD SENTINEL | $43 | |
ARGO MOLE | < | APOLLO MEDIVAC | $43 | |
ARGO MOLE | < | ESPERIA VANDUUL BLADE | $43 | |
ARGO MOLE | < | VANGUARD HARBINGER | $27 | |
ARGO MOLE | < | REDEEMER | $70 | |
ARGO MOLE | < | HULL C | $70 | |
ARGO MOLE | < | APOLLO TRIAGE | $70 | |
ARROW | ||||
ARROW | < | AURORA MR | $50 | |
ARROW | < | MUSTANG ALPHA | $50 | |
ARROW | < | C8X PISCES EXPEDITION | $35 | |
ARROW | < | 100i | $30 | |
ARROW | < | AVENGER TITAN | $25 | |
ARROW | < | RELIANT KORE | $15 | |
CATERPILLAR BEST IN SHOW EDITION | ||||
CATERPILLAR BISE | < | VANGUARD HARBINGER | $100 | |
CORSAIR | ||||
CORSAIR | < | TAURUS | $60 | |
CRUCIBLE | ||||
CRUCIBLE | < | STARFARER GEMINI | $21 | |
CUTLASS BLACK BEST IN SHOW EDITION | ||||
CUTLASS BLACK BISE | < | GLADIUS | $70 | |
CUTLASS RED Subscriber | ||||
CUTLASS RED Subscriber | < | F7C-S HORNET GHOST | $25 | |
CUTLASS BLUE | ||||
CUTLASS BLUE | < | PROSPECTOR | $30 | |
DEFENDER | ||||
DEFENDER | < | CORSAIR | $15 | |
DEFENDER | < | HORNET F7C-M HEARTSEEKER | $37 | |
GLADIUS | ||||
GLADIUS | < | AURORA MR | $65 | |
GLADIUS | < | MUSTANG ALPHA | $65 | |
GLADIUS | < | C8X PISCES EXPEDITION | $50 | |
GLADIUS | < | 100i | $45 | |
GLADIUS | < | AVENGER TITAN | $40 | |
GLADIUS | < | RELIANT KORE | $30 | |
GLADIUS | < | ARROW | $20 | |
HAMMERHEAD | ||||
HAMMERHEAD | < | CARRACK | $150 | |
HAMMERHEAD | < | CARRACK EXPEDITION W/C8X | $100 | |
HULL C | ||||
HULL C | < | CATERPILLAR | $175 | |
MERCHANTMAN | ||||
MERCHANTMAN | < | STARFARER GEMINI | $300 | |
MERCHANTMAN | < | ARGO MOLE | $345 | |
NAUTILUS | ||||
NAUTILUS | < | CARRACK | $175 | |
PERSEUS | ||||
PERSEUS | < | CARRACK Expedition W/C8X | $40 | |
PERSEUS | < | CARRACK | $90 | |
PERSEUS | < | ORION | $115 | |
PERSEUS | < | 600I EXPLORER | $220 | |
PERSEUS | < | MERCHANTMAN | $248 | |
PERSEUS | < | ARGO MOLE | $380 | |
PERSEUS | < | ANDROMEDA | $485 | |
POLARIS | ||||
POLARIS | < | PERSEUS | $70 | |
POLARIS | < | HAMMERHEAD | $70 | |
POLARIS | < | NAUTILUS | $60 | |
POLARIS | < | CARRACK | $250 | |
RECLAIMER BIS 2949 | ||||
RECLAIMER BIS 2949 | < | VALKYRIE | $300 | |
SAN'TOK.YĀI | ||||
SAN'TOK.YĀI | < | HORNET F7C-M HEARTSEEKER | $37 |
2024.05.13 19:50 Professional_Disk131 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by Professional_Disk131 to trakstocks [link] [comments] https://preview.redd.it/gt0eb6ute80d1.png?width=300&format=png&auto=webp&s=c449da417057e0dc2bbede7f7a1fb3cdc5812e24 NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.13 19:49 Professional_Disk131 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by Professional_Disk131 to smallstreetbets [link] [comments] https://preview.redd.it/3cux3q0se80d1.png?width=300&format=png&auto=webp&s=a1151dcc8641648f9cd2683d18c602e035858280 NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.05.13 19:49 Professional_Disk131 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by Professional_Disk131 to Canadapennystocks [link] [comments] https://preview.redd.it/qf1mrsgoe80d1.png?width=300&format=png&auto=webp&s=43f721d702584bb6ce21af1102407ea68c138734 NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries. Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |